Covid-19: Razvoj vakcine, imunitet i primena medikamenata

[vememah]

Izraelci i Indijci razvili oralnu vakcinu koja ima trostruku zaštitu (targetira i šiljak i membranu i envelopu) pa će verovatno biti otpornija na mutirane varijante. Klinička ispitivanja započinju u 2. kvartalu.

 

 

Edited March 22, 2021 by vememah

[precog]

cool, ali bih sacuvao optimizam dok ne dobijemo rezultate klinickih istrazivanja.

[adam]

radi se na tome vec neko vreme. meni komsinica koja ovde radi za nhs rekla jos zimus da indijci ovo prave i da su lekari oko nje dosta optimisticni. ja zaboravio kao i razno, ne udubljujem se dok se ne pokaze da radi. al evo sad me podsetiste pa se nesto mislim - ako nisu odustali, mozda stvarno ima nade.

 

rekoh sta sam imao a sad cu opet da zaboravim.

[Amos]

Sta je bilo sa izraelskim lekom o kome se pisalo pre jedno mesec dana cesto, a onda kao da je u zemlju propao? Da li je to uslo negde u upotrebu? Vememaše na tebe računam da imaš spreman link 

[Moracikus]

Sprdnja.

Ili su ovi iz Oksforda totalno neozbiljni ili je big pharma odlucna u namjeri da unisti ovaj projekat.

[vememah]

To je ovo:

 

Quote

Tuesday, March 23, 2021

NIAID Statement on AstraZeneca Vaccine
Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial. The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data. We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.

Authorization and guidelines for use of the vaccine in the United States will be determined by the Food and Drug Administration and Centers for Disease Control and Prevention after thorough review of the data by independent advisory committees.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

https://www.nih.gov/news-events/news-releases/niaid-statement-astrazeneca-vaccine

 

 

 

 

 

Edited March 23, 2021 by vememah

[Krošek]

Pretpostavljam da su u svojoj prijavi podneli dokumentaciju u kojoj se na jednom mestu pominju stari brojevi iz sporne studije iz 2020, a na drugom novi iz februara.

[vememah]

Moguće da je pozivanje na duži interval problem pošto ni sad nisu obavili testiranje s dužim razmakom, već je on bio 4 nedelje. Evo tog dela iz saopštenja:

 

Quote

Previous trials have shown that an extended interval of up to 12 weeks demonstrated greater efficacy, which was also supported by immunogenicity data. This evidence suggests administration of the second dose with an interval longer than four weeks could further increase efficacy and accelerates the number of people who can receive their first dose.

https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint.html

[Lancia]

Spanska vakcina CSIC ulazi u trecu fazu ispitivanja, bice u vidu nosnog spreja kao jedna doza ili u vidu klasicne inekcije u dve doze, ukljucuje otpornost na sve postojece mutacije virusa i bice efikasna 100%, navodno je karakterise stertilni imunitet, nemogucnost zaraze i nemogucnost prenosenja virusa. Predvidja se da ce biti u opticaju pocetkom sledece godine.

[Aleksija]

1 minute ago, Lancia said:

Spanska vakcina CSIC ulazi u trecu fazu ispitivanja, bice u vidu nosnog spreja kao jedna doza ili u vidu klasicne inekcije u dve doze, ukljucuje otpornost na sve postojece mutacije virusa i bice efikasna 100%, navodno je karakterise stertilni imunitet, nemogucnost zaraze i nemogucnost prenosenja virusa. Predvidja se da ce biti u opticaju pocetkom sledece godine.

al se hvalimo 

[Lancia]

1 minute ago, Aleksija said:

al se hvalimo 

Pa da, dok dodje, ima svi ovde da pocrkamo. Moje malo ostrvo je sad najgore u arhipelagu, usli smo u crvenu zonu, jer magarci od domorodaca ne mogu bez prisnog druzenja. Zatvorise i Lidl, jer je personal zarazen.

[Aleksija]

Just now, Lancia said:

Pa da, dok dodje, ima svi ovde da pocrkamo. Moje malo ostrvo je sad najgore u arhipelagu, usli smo u crvenu zonu, jer magarci od domorodaca ne mogu bez prisnog druzenja. Zatvorise i Lidl, jer je personal zarazen.

uh, bezveze, vi ste mi nekako delovali kao bezbedno mesto. cuvajte se.

[Aleksija]

4 hours ago, Moracikus said:

Sprdnja.

Ili su ovi iz Oksforda totalno neozbiljni ili je big pharma odlucna u namjeri da unisti ovaj projekat.

 

deluje da su se ipak malo okomili...

[Jumanji]

[vememah]

WaPost piše da je Astrazeneka izgleda namerno birala starije podatke koji daju veću efikasnost.

 

 

Quote

On Monday, AstraZeneca and academic scientists trumpeted a vaccine that was 79 percent effective in its large U.S. clinical trial. That news release triggered concern among independent monitors who had seen more recent data, because when an additional month was taken into account, the effectiveness ranged from 69 to 75 percent.

...

“The DSMB is concerned that AstraZeneca chose to use data that was already outdated and potentially misleading in their press release,” the letter states. The data “they chose to release was the most favorable for the study as opposed to the most recent and most complete. Decisions like this are what erode public trust in the scientific process.”

...

In other circumstances, this turmoil might be seen as a technical issue, because the additional data doesn’t appear to overturn the fundamental finding that the vaccine works. AstraZeneca released a statement Tuesday promising that the full analysis of its data would be available within 48 hours and indicated the results would be consistent with the analysis released Monday.

“We will immediately engage with the independent data safety monitoring board to share our primary analysis with the most up to date efficacy data,” the statement said.

But it appears to be the latest in a series of self-inflicted wounds from the team behind the vaccine, which has had months of stumbles involving messy science and bungled communication.

 

Federal officials were taken aback by the board’s allegations. One said the way that AstraZeneca handled the results was the equivalent of “telling your mother you got an A in a course, when you got an A in the first quiz but a C in the overall course.” Another said the disclosure by the board would inevitably hurt the company’s credibility with U.S. regulators.

https://www.washingtonpost.com/world/astrazeneca-oxford-vaccine-concerns/2021/03/23/2f931d34-8bc3-11eb-a33e-da28941cb9ac_story.html

 

AZ pak u saopštenju kaže da su brojke novije "primarne" analize slične onima iz starije "provizorne", koje su objavili:

 

Quote

We have reviewed the preliminary assessment of the primary analysis and the results were consistent with the interim analysis.

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/update-following-statement-by-niaid-on-azd1222-us-phase-iii-trial-data.html

 

Videćemo kad ih objave kolika će razlika zaista biti.

Edited March 24, 2021 by vememah